Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site.

/in

Cheng HD, Grimm SK, Gilman MS, Gwom LC, Sok D, Sundling C, Donofrio G, Karlsson Hedestam GB, Bonsignori M, Haynes BF, Lahey TP, Maro I, von Reyn CF, Gorny MK, Zolla-Pazner S, Walker BD, Alter G, Burton DR, Robb ML, Krebs SJ, Seaman MS, Bailey-Kellogg C, Ackerman ME. Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. JCI Insight. 2018 Mar 8;3(5).

NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation.

/in

Hogan LE, Körner C, Hobbs K, Simoneau CR, Thanh C, Gibson EA, Palmer CD, Pandit A, Marty FM, Kuritzkes DR, Jost S, Ritz J, Henrich TJ. NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. (2018) Blood Advances. 2(12):1412-1416.

TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy.

/in ,

Lim SY, Osuna CE, Hraber PT, Hesselgesser J, Gerold JM, Barnes TL, Sanisetty S, Seaman MS, Lewis MG, Geleziunas R, Miller MD, Cihlar T, Lee WA, Hill AL, Whitney JB. TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy. Sci Transl Med. 2018 May 2;10(439).

Adenovirus vector vaccination impacts NK cell rheostat function following lymphocytic choriomeningitis virus infection.

/in

Blass E, Aid M, Martinot AJ, Larocca RA, Kang ZH, Badamchi-Zadeh A, Penaloza-MacMaster P, Reeves RK, Barouch DH. Adenovirus vector vaccination impacts NK cell rheostat function following lymphocytic choriomeningitis virus infection. J. Virol. 2018; 92:e02103-17.

First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1

/in

Stephenson KE, Keefer MC, Bunce CA, Frances D, Abbink P, Maxfield LF, Neubauer GH, Nkolola J, Peter L, Lane C, Park H, Verlinde C, Lombardo A, Yallop C, Havenga M, Fast P, Treanor J, Barouch DH. First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. PLoS One 2018; 13:e0205139.

NL. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.

/in

Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, Jarman RG, Sondergaard E, Tennant J, Ansel JL, Mills K, Koren M, Robb ML, Barrett J, Thompson J, Kosel AE, Dawson P, Hale A, Tan CS, Walsh SR, Meyer KE, Brien J, Crowell TA, Blazevic A, Mosby K, Larocca RA, Abbink P, Boyd M, Bricault CA, Seaman MS, Basil A, Walsh M, Tonwe V, Hoft DF, Thomas SJ, Barouch DH, Michael NL. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet. 2018 Feb 10;391(10120):563-571. doi: 10.1016/S0140-6736(17)33106-9. Epub 2017 Dec 5. PubMed PMID: 29217375; PubMed Central PMCID: PMC5884730.

Tracking KLRC2(NKG2C)+ memory and memory-like NK cells in rhCMV+ and SIV+ rhesus macaques.

/in

Ram, D.R., Manickam, C., Hueber, B., Permar, S.R., Varner, V., and Reeves, R.K. Tracking KLRC2(NKG2C)+ memory and memory-like NK cells in rhCMV+ and SIV+ rhesus macaques. 2018. PLoS Pathog. 14(5):e1007104. PMID: 29851983. PMCID: PMC5997355

First-in-human randomized, controlled trial of mosaic HIV-1 immunogens delivered via a modified vaccinia Ankara vector.

/in , ,

Baden LR, Walsh SR, Seaman MS, Cohen YZ, Johnson JA, Licona JH, Filter RD, Kleinjan JA, Gothing JA, Jennings J, Peter L, Nkolola J, Abbink P, Borducchi EN, Kirilova M, Stephenson KE, Pegu P, Eller MA, Trinh HV, Rao M, Ake JA, Sarnecki M, Nijs S, Callewaert K, Schuitemaker H, Hendriks J, Pau MG, Tomaka F, Korber BT, Alter G, Dolin R, Earl PL, Moss B, Michael NL, Robb ML, Barouch DH; IPCAVD006/RV380/HIV-V-A002 Study Group. First-in-human randomized, controlled trial of mosaic HIV-1 immunogens delivered via a modified vaccinia Ankara vector. J. Infect. Dis. 2018; 218:633-644.

Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentrate.

/in

Bendapudi PK, Robbins A, LeBoeuf N, Pozdnyakova O, Bhatt A, Duke F, Sells R, McQuiston J, Humrighouse B, Rouaisnel B, Colling M, Stephenson KE, Saavedra A, Losman JA. Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentrate. Blood Adv. 2018 Nov 13;2(21):2917-2921. doi: 10.1182/bloodadvances.2018024430. PubMed PMID: 30396911; PubMed Central PMCID: PMC6234356.

Zika virus research models

/in

Kublin JL, Whitney JB. Zika virus research models. Virus Res. 2018 Aug 2;254:15-20. doi: 10.1016/j.virusres.2017.07.025. Epub 2017 Aug 12. PMID: 28811170; PMCID: PMC5809325.